# Clinical Pharmacology Training Program

> **NIH NIH T32** · THOMAS JEFFERSON UNIVERSITY · 2020 · $774,341

## Abstract

PROJECT SUMMARY/ABSTRACT
This is a proposal to continue the evolution of postdoctoral training in clinical pharmacology as a collaborative
program in pediatric and adult therapeutics in the joint program between Thomas Jefferson University (TJU) with
the Children’s Hospital of Philadelphia (CHOP). The goal is to realize one key objective of the NIGMS-NICHD
collaboration in clinical pharmacology as a leading joint program training clinician investigators to translate novel
discoveries into therapeutic paradigms that transform disease management for children and adults. The program
is designed for eight postdoctoral fellows, including MDs and MD-PhDs, and PharmDs, focused on human
pharmacology and therapeutics. While training integrates therapeutics across the developmental continuum for
fellows, half pursue careers in pediatric and half in adult clinical pharmacology to address shortages in these
communities of practice nationally. The program, which is two years with the potential to extend for a third year,
expands a well-established curriculum of didactic coursework, conferences, and rotations (20% effort) and
research (80% effort). The breadth of pediatric and adult clinical pharmacology is delivered using a framework
built on the TJU Training Program in Human Investigation (former NIH K30 Program). Courses cover clinical
pharmacology, clinical trials design, statistics, pharmacoepidemiology, pharmacometrics, drug development,
ethics, management, leadership, grant writing and presentation skills. Advanced training in academic and
industrial pharmacometrics is an elective offering. Conferences include journal club in human therapeutics,
research ethics, and seminars in human therapeutics. Rotations provide experience in the critical analysis of
the scientific literature on the editorial board of the Annals of Internal Medicine; critical review of pediatric
(CHOP) and adult (TJU) human subjects research on institutional review boards (IRBs); clinical trial execution
in the TJU Clinical Research Unit; special issues in pediatric therapeutics on the CHOP formulary and
investigational new drug (IND) committees, or analytic method development to support trainee pharmacokinetic
studies. Fellows customize their education by selecting electives congruent with career aspirations, including
drug development at Merck and/or rotation at the Food and Drug Administration (FDA). The majority of fellows’
time is focused on independent, hypothesis-driven research. Opportunities in pediatric and adult experimental
therapeutics are offered by 54 preceptors representing 9 broad areas of distinction, including cancer,
cardiopulmonary medicine, neurosciences, virology and immunology, connective tissue biology, pediatric
oncology, systems and clinical pharmacology, gastroenterology, and pediatric therapeutics. Preceptors are
selected based on their productive research programs related to therapeutics, training success, and commitment
to train fellows. This program wi...

## Key facts

- **NIH application ID:** 9855948
- **Project number:** 2T32GM008562-26
- **Recipient organization:** THOMAS JEFFERSON UNIVERSITY
- **Principal Investigator:** WALTER K KRAFT
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $774,341
- **Award type:** 2
- **Project period:** 1995-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9855948

## Citation

> US National Institutes of Health, RePORTER application 9855948, Clinical Pharmacology Training Program (2T32GM008562-26). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9855948. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*